Trial Profile
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Cetuximab
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 26 Aug 2020 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 26 Aug 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
- 26 Aug 2020 Status changed from active, no longer recruiting to recruiting.